Peculiarities of long-COVID-19 and treatment strategy: a clinical case

Autor: Volyansky, A. Yu., Davydova, T. V., Kuchma, I. Yu., Kuchma, M.V., Yudin, I.P.

Introduction. Over the past two years, the world has faced a serious problem ��� the emergence of a highly contagious and virulent new type of coronavirus ��� SARS-CoV-2, which causes acute respiratory disease - COVID-19. Disease with COV

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b5c0b36df9d579cb6c775dd8e97a206

The questions of allergy and anti-tuberculosis immunity in the works of M.M. Tsehnovitser

Autor: Kuchma, I, Moiseenko, T

Publikováno v: Annals of Mechnikov's Institute; № 3 (2014); 60-65

The mechanism of anti-tuberculosis immunity drew the attention of scientists since the established of the infectious nature of tuberculosis. The famous ukrainian microbiologist and immunologist M.M. Tsehnovitser in period from 1921 to 1940 years spen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=scientific_p::b9cbb7e77588bfca17b89ff845744ea3
http://journals.uran.ua/ami/article/view/208122

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Prospective multicenter study of HX575 (biosimilar epoetin-alpha) in patients with chronic kidney disease applying a target hemoglobin of 10 – 12 g/dl

Autor: Hörl WH, Locatelli F, Haag Weber M, Ode M, Roth K, Lhotta K, Loipl J, Huspek M, Gstöttenbauer K, Karagyozova R, Monova D, Shikov P, Yovchev T, Bazeva P, Nenchev N, Charasse C, Bockreiss N, Buhl M, Dellanna F, Dragoun GP, Goller M, Klingbeil A, Knee J, Krallinger R, Menzer T, Perschon G, Toussaint K, Wichelhaus T, Kreuzer K, Brückner D, Leistikow F, Marsen T, Sacherer K, Zimmermann U, Kohnle M, Riedasch M, Brehm K, Vogt J, Morgenroth A, Herrnberger S, Zeh M, Dammerboer C, Hofmann T, Kraemer Guth A, Wilpert J, Pröschild F, Krämer B, Lang R, Zanker B, Lubrich Birkner I, Hemstege M, Jäkel D, Perino S, Riedl B, Assenmacher A, Albertazzi A, Colussi G, Garibotto G, Villa G, Gesualdo L, Triolo G, Cusi D, Gallieni M, Quarello F, Malberti F, Tarchini R, Di Iorio BR, Di Luca M, Bordoni E, Brunori G, Della Grotta F, Fracasso A, Guerrini E, Ragaiolo M, Costanzo R, Teatini U, Dimitrov S, Sikole A, Zabzun M, Janakievska P, Petrovska T, Rzanikoski T, Alceva M, Panova B, Daniewska D, Klatko W, Stryjewski D, Książek A, Kopecka Mechlińska L, Kędzierski P, Nowicki M, Szurkowski M, Papliński M, Trafny R, Kuczera M, Sokalski A, Rydzewski A, Liberek T, Uzar J, Bako GC, Ionescu D, Voiculescu M, Ardelean LC, Pitea IV, Demina L, Borsukov A, Marasaev V, Fedosseev A, Dudar I, Kolesnyk M, Kostynenko T, Kuchma I, Kuriata O, Lesovoy V, Martynyuk L, Nikonenko O., STEFONI, SERGIO

Publikováno v: Clinical Nephrology. 78:24-32

HX575 was approved in the European Union in August 2007 as the first-ever biosimilar epoetin-α product. The present study extended the safety database on HX575 by monitoring adverse events (AEs) in clinical practice. Hemoglobin (Hb) levels and HX575

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd25c473755e19eb98bcd6567f570433
https://doi.org/10.5414/cn107440